垂体腺瘤细胞增殖活性和肿瘤生长方式的相关性研究

目的：探讨垂体腺瘤细胞增殖活性和其侵袭性生长方式之间的相关性。方法：采用单克隆抗体MIB－1免疫组织化学染色，确定110例垂体瘤的Ki－67标记指数。结果：平均标记指数是2．65％。患者年龄、肿瘤大小对标记指数无影响。非侵袭组是2．01％，侵袭组是3．71％，P＝0．027，有显著性差异。侵袭蝶窦组是5．58％。功能性腺瘤是3．09％，非功能性腺瘤是1．98％，P＝0．14，两者之间无显著性差异。ACTH腺瘤的标记指数是5．47％，其他功能性腺瘤是2．33％，P＝0．01，有显著性差异。患者年龄、肿瘤大小对标记指数无影响。结论：肿瘤细胞的增殖活性与垂体瘤的侵袭性有关，但不是肿瘤发生侵袭的唯一因素。     

侵袭性垂体腺瘤中CD44与Ki-67表达的相关性

目的探讨细胞粘附分子CD44、细胞增值核抗原Ki-67在侵袭性垂体腺瘤中的表达及意义并探讨二者之间的关系。方法用免疫组化法检测CD44s、CD44v5、Ki-67在20例侵袭性垂体腺瘤和18例非侵袭性垂体腺瘤中的表达。结果CD44s和Ki-67在侵袭性垂体腺瘤组中表达高于非侵袭性垂体腺瘤组(P<0.01),且二者在垂体腺瘤中的表达呈正相关。CD44v5在侵袭性和非侵袭性垂体腺瘤中表达无明显差异(P>0.05)。结论CD44s和Ki-67与垂体腺瘤的侵袭性生长行为有关,二者协同作用,在侵袭性垂体腺瘤的发生、发展中起重要作用,可作为侵袭性垂体腺瘤诊断和判断预后的重要生物学指标。     

VEGF、Ki-67蛋白与垂体腺瘤侵袭性及复发相关性的研究

目的分析VEGF、Ki-67蛋白在垂体腺瘤中的表达,探讨VEGF、Ki-67与垂体腺瘤侵袭性与复发之间的关系。方法采用免疫组化S-P法检测上述两种蛋白在60例垂体腺瘤中的表达。结果VEGF、Ki-67在侵袭性垂体腺瘤组的阳性表达显著高于非侵袭垂体腺瘤组,复发组显著高于非复发组（P〈0．05）,VEGF与Ki-67的表达与垂体腺瘤的侵袭及复发有显著相关性（rs=0．4896 P〈0．05）。结论VEGF与Ki正7的高表达与垂体腺瘤的侵袭性与复发密切相关,VEGF和Ki-67蛋白可作为预测垂体腺瘤侵袭性及可能复发的生物学指标,也可作为指导术后个体化治疗的客观参考指标。     

侵袭性垂体腺瘤的基因研究

垂体腺瘤约占颅内肿瘤的10％，每年发病率为0．5／10万-8．2／10万，而临床上静息的微腺瘤在无选择尸解中高达23％。大部分垂体腺瘤是良性的，而文献报道远处转移几乎是垂体腺癌唯一的诊断证据。介于良性腺瘤和腺癌二者之间的、具有恶性肿瘤生物学行为的肿瘤，称为侵袭性垂体腺瘤，其生长特征是垂体瘤呈侵袭性生长，发病率高（33％-35％），治愈率低（17％）。据文献报道，侵袭性垂体腺瘤的发生率占垂体腺瘤的6％-85％，如何在术前诊断侵袭性垂体腺瘤目前仍是一个难题。临床上对于有以下情况时，一般考虑垂体     

人脑侵袭性垂体腺瘤的生物学活性

目的 侵袭是恶性肿瘤的生物学特征,而部分人脑垂体腺瘤也具有.本实验研究该类腺瘤细胞DNA倍体特征和增殖活性.方法:通过流式细胞术和细胞图像分析技术检测.结果:垂体腺瘤侵袭性和异常DNA倍体垂体腺瘤细胞比例相关密切.结论:从细胞DNA倍体角度分析,侵袭性垂体腺瘤具有恶性生长倾向.     

侵袭性垂体腺瘤的分子生物学研究进展

垂体腺瘤为来源于垂体前叶腺细胞的单克隆腺瘤,根据其生物学行为分为非侵袭性与侵袭性。侵袭性垂体腺瘤生物学行为介于恶性与良性腺瘤之间,它可破坏鞍区骨质,侵袭海绵窦等鞍区结构,其高复发率、低治愈率以及术后并发症等给临床治疗带来很大的困难[1]。近年来,随着细胞生     

垂体腺瘤中黏蛋白1的表达与肿瘤侵袭性的关系

目的 探讨垂体腺瘤中黏蛋白1（MUC1）的表达与肿瘤侵袭性的关系.方法 采用免疫组织化学法检测26例侵袭性垂体腺瘤和29例非侵袭性垂体腺瘤患者肿瘤组织中MUC1的表达.结果 侵袭性垂体腺瘤组织中MUC1高表达,阳性率为76.92％（20/26）;非侵袭性垂体腺瘤组织中MUC1为弱阳性表达或不表达,阳性率为27.57％（8/29）,两者差异有统计学意义（x2=13.35,P＜ 0.01）.功能性垂体腺瘤组织中MUC1阳性率为44.82％（13/35）,非功能垂体腺瘤中MUC1阳性表达率为75.00％（15/20）,两者差异无统计学意义（x2=6.13,P＞ 0.01）.结论 MUC1在侵袭性垂体腺瘤组织中的表达及分布特点可作为垂体腺瘤侵袭性的辅助鉴别诊断指标,有可能作为垂体腺瘤免疫治疗的靶抗原.     

Ki-67单抗标记指数与侵袭性垂体腺癌复发相关性研究

〔目的〕研究ki－67单抗标记指数（LabellingIndexLI）在评估侵袭性垂体腺瘤术后复发的作用。［方法］将16例侵袭性垂体腺瘤术后肿瘤标本用ABC法检测ki-67LIl,根据术后随访的复发资料,分复发组（6例）和未复发组（10例）两组,再分析和比较两组的Ki-67LI.[结果]在复发组中的Ki－67LI(63．8土4．5)％显著高于未复发组（21．7土2．3）%,P＜0．01;在所有激素类型中,多激素型的ki－67LI为最高。[结论]你一67LI与侵袭性垂体脉瘤术后复发相关,可作为预测垂体脉瘤术后潜在复发的一项指标。     

Ki-67在垂体瘤、脑膜瘤、脑血管母细胞瘤中的表达及其临床意义

背景与目的：垂体瘤、脑膜瘤和脑血管母细胞瘤作为颅内常见良性肿瘤，术后常有复发，本研究探讨Ki-67在三者中的表达及其与复发的关系。方法：采用免疫组化SP法．检测Ki-67在56例垂体瘤、60例脑膜瘤和43例脑血管母细胞瘤中的表达．以显微镜下细胞核出现棕黄色颗粒计算Ki-67标记指数，并进行统计学分析。结果：Ki-67表达在垂体瘤侵袭性组高于非侵袭性组，脑膜瘤与脑血管母细胞瘤的复发组高于非复发组，差异均有统计学意义（P〈0．05）。结论：检测垂体瘤、脑膜瘤和脑血管母细胞瘤中Ki-67表达对评估肿瘤术后复发有一定参考价值。     

Relationship between Gene Expression of bFGF and Proliferative Activity in Meningioma

OBJECTIVE To study the relationship between bFGF gene expression and proliferative activity in meningiomas.METHODS Thirty-seven samples of meningioma were examed using Northern hybridization for bFGF-gene expression and immunohistochemi- stry for bFGF protein expression and the Ki-67LI.RESULTS bFGF mRNA was detected in 22 meningiomas of Grade Ⅰ and in all samples of Grade Ⅱ and Ⅲ. Six of the Grade Ⅰ tumors were negative,giving an overall positive rate of 83.8 % for bFGF mRNA. Autoradiography was conducted using a thin scaning apparatus. bFGF mRNA expression compared to that for β-actin was 0.34±0.06 for Grade Ⅰ tumors compared to 0.82±0.12 for Grade Ⅱ and Ⅲ tumors. The difference was highly significant (P＜0.001). The results of immunohistochemistry showed that the number of the positive cells for the bFGF protein was 29.7±7.6% in Grade Ⅰ tumors and 63.2±11.7 % in Grade Ⅱ plus Ⅲ, resulting in a significant difference between them (P＜0.001). The Ki-67LI was found to be 2.8±1.1% in Grade Ⅰ and 6.5±1.3 % in Grade Ⅱ plus Ⅲ. The former was significantly lower than the later (P＜0.001).CONCLUSION The expression of bFGF was correlated well with the malignancy of the meningiomas.     

Association of Proliferative Activity in Invasive Ductal Carcinoma Breast in Pakistani Population

Background: Personalized medicine has played very important role in management of breast cancer.  Proliferative index is one among the prognostic and predictive factor but unfortunately due to varied reports , no definite consensus and routine medical practice has been approved for it. The objective of the study is to observe the association of Ki-67 index using St. Gallen Conference criteria in invasive ductal carcinoma breast in Pakistani Population. Methods: Eighty-three patients with confirmed light microscopic diagnosis of primary invasive ductal carcinoma were recruited in this prospective study . Expression of Ki67 was determined by classifying as low (<15%) and high (>15%) Ki67 in tumour. Statistical analysis was performed to observe the association of Ki-67 with clinicopathological parameters and molecular group (i.e., Luminal A, Luminal B, Her2 enriched and triple negative). Results: Out of 83 patients, 73.5% of patients showed >15% Ki67 (p value <0.001). High expression of Ki 67 (>15%) was observed in 3.6%, 21.7% and 48.2 % of Nottingham grade I, II and III (p value=0.017) respectively.  Among molecular group, high expression of Ki67 was observed 20.5% in Luminal A, 9.6% in Luminal B, 15.7% in Her2 enriched and 27.7% in triple negative groups (p= 0.017). There was no significant association observed in expression of Ki 67 among lymph node stage, tumour stage and Nottingham prognostic index. Conclusion: Higher Ki-67 reactivity is usually associated with higher-grade morphology of tumour. It can act as an independent predictor in assessment of tumour behavior. However, larger validation clinical studies are still required for confirmation of its importance and for routine practice.     

侵袭性垂体腺瘤相关抑癌基因研究进展

侵袭性垂体腺瘤是一类特殊的垂体腺瘤,可向周围组织侵犯,危害性大,但发病机制未明。目前已证实垂体腺瘤是由单克隆发生的,可能由原始干细胞基因突变导致细胞增殖引起,即可能与抑癌基因的突变密切相关。因此,对侵袭性垂体腺瘤相关抑癌基因的研究至关重要。为在分子生物学层面研究垂体腺瘤侵袭性机制提供科学依据。     

垂体瘤术后复发因素分析

本文报道21例术后复发性垂体瘤,占同期手术的19.4%。男10例,女11例。年龄24～67岁,平均36岁。复发时间为术后2个月至5年7个月,平均2年8个月。均经 CT 扫描证实。其复发诊断标准为术后症状及体征改善者再度出现以下表现之一:①视力下降、视野缺损等临床症状;②无临床症状,但 CT 扫描发现有肿瘤复发征象;③仅出现内分泌激素重新升高。复发因素包括治疗方法、肿瘤病理特性及垂体瘤的侵润性、多发性等。     

伽玛刀治疗垂体瘤的经验

报道１９９３年１０月～１９９４年４月经伽玛刀治疗的垂体瘤１００例，７８例随访了６～１２个月，其中４９例随访了ＭＲ，１２例复查了血ＰＲＬ水平，１０例复查了血ＧＨ水平。结果表明，病人的症状控制率及肿瘤大小控制率均为１００％，治疗前后血ＰＲＬ、ＧＨ差别均有显著性，故认为伽玛刀治疗垂体瘤近期效果良好。对治疗剂量、适应证及相关问题进行了探讨。